<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Moxifloxacin (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Moxifloxacin (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Moxifloxacin (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9845" href="/d/html/9845.html" rel="external">see "Moxifloxacin (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="12263" href="/d/html/12263.html" rel="external">see "Moxifloxacin (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F9347830"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious adverse reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinopathy and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue moxifloxacin immediately and avoid the use of fluoroquinolones in patients who experience any of these serious adverse reactions. Because fluoroquinolones have been associated with serious adverse reactions, reserve moxifloxacin for use in patients who have no alternative treatment options for the following indications: acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myasthenia gravis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid moxifloxacin in patients with known history of myasthenia gravis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9347899"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Avelox [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869435"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Moxifloxacin;</li>
<li>APO-Moxifloxacin;</li>
<li>Auro-Moxifloxacin;</li>
<li>Avelox [DSC];</li>
<li>BIO-Moxifloxacin [DSC];</li>
<li>JAMP-Moxifloxacin;</li>
<li>M-Moxifloxacin;</li>
<li>Mar-Moxifloxacin;</li>
<li>RIVA-Moxifloxacin [DSC];</li>
<li>SANDOZ Moxifloxacin;</li>
<li>TEVA-Moxifloxacin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F11163942"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Fluoroquinolone</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Respiratory Fluoroquinolone</span></li></ul></div>
<div class="block don drugH1Div" id="F53462665"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Fluoroquinolones should not typically be used as first-line therapy due to their adverse effect profile and risk of development of bacterial resistance. Only use in situations when there is no safe and effective substitute available (eg, drug resistance, allergy) or when oral fluoroquinolone therapy provides a reasonable alternative to parenteral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940800','lexi-content-ref-NelsonPed.1','lexi-content-ref-26865283','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940800','lexi-content-ref-NelsonPed.1','lexi-content-ref-26865283','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d993762-69b4-4a3a-9965-be573ca3421f">Anthrax, meningitis or disseminated infection when meningitis cannot be ruled out; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax, meningitis or disseminated infection when meningitis cannot be ruled out; treatment (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consult public health officials for event-specific recommendations. Administer as part of an appropriate combination regimen for at least 2 to 3 weeks and until patient is clinically stable; treatment must be followed by prophylaxis, for a total antibiotic course of 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">GA 32 to 37 weeks, PNA ≤28 days: IV: 5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GA &gt;37 weeks, PNA ≤28 days: IV: 10 mg/kg/dose every 24 hours.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F13658491"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Fluoroquinolones should not typically be used as first-line therapy due to their adverse effect profile and risk of development of bacterial resistance. Only use in situations when there is no safe and effective substitute available (eg, drug resistance, allergy) or when oral fluoroquinolone therapy provides a reasonable alternative to parenteral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940800','lexi-content-ref-NelsonPed.1','lexi-content-ref-26865283','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940800','lexi-content-ref-NelsonPed.1','lexi-content-ref-26865283','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children &lt;2 years: Oral, IV: 6 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NelsonPed.1','lexi-content-ref-31310051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NelsonPed.1','lexi-content-ref-31310051'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;6 years: Oral, IV: 5 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NelsonPed.1','lexi-content-ref-31310051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NelsonPed.1','lexi-content-ref-31310051'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;12 years: Oral, IV: 4 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NelsonPed.1','lexi-content-ref-31310051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NelsonPed.1','lexi-content-ref-31310051'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents &lt;18 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NelsonPed.1','lexi-content-ref-31310051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NelsonPed.1','lexi-content-ref-31310051'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;45 kg: Oral, IV: 4 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">≥45 kg: Oral, IV: 400 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Oral, IV: 400 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NelsonPed.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NelsonPed.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d993762-69b4-4a3a-9965-be573ca3421f">Anthrax, meningitis or disseminated infection when meningitis cannot be ruled out; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax, meningitis or disseminated infection when meningitis cannot be ruled out; treatment: Note:</b> Consult public health officials for event-specific recommendations. Administer as part of an appropriate combination regimen for at least 2 to 3 weeks and until patient is clinically stable; treatment must be followed by prophylaxis, for a total antibiotic course of 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents &lt;18 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>): Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months and Children &lt;2 years: IV: 6 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;6 years: IV: 5 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to &lt;12 years: IV: 4 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;45 kg: IV: 4 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">≥45 kg: IV: 400 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: IV: 400 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02b4604f-7121-4a88-88dd-a5008cafb941">Intra-abdominal infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated (alternative agent): Note:</b> Beta-lactam-based regimens are preferred; moxifloxacin may be less effective as compared to beta-lactam comparators (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-28085573','lexi-content-ref-29356761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-28085573','lexi-content-ref-29356761'])">Ref</a></span>). In clinical trials, patients ≥20 kg received ≥3 days of IV therapy prior to transitioning to oral therapy; patients &lt;20 kg completed course using IV therapy. Total duration of therapy was 5 to 14 days, though a small number of patients received treatment for &gt;14 days (maximum: 24 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29356761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29356761'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents &lt;18 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29356761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29356761'])">Ref</a></span>): Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months and Children &lt;2 years: IV, Oral: 6 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NelsonPed.1','lexi-content-ref-29356761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NelsonPed.1','lexi-content-ref-29356761'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;6 years: IV, Oral: 5 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to &lt;12 years: IV, Oral: 4 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;45 kg: IV, Oral: 4 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">≥45 kg: IV, Oral: 400 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: IV, Oral: 400 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d4f4fe77-94d1-4c1c-bbdc-85a4ab416dc3">Nontuberculous mycobacterial infection, pulmonary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nontuberculous mycobacterial infection, pulmonary:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 7.5 to 10 mg/kg/dose once daily; maximum dose: 400 mg/dose. Use as part of an appropriate combination regimen until patient is culture negative on therapy for ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29054853','lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29054853','lexi-content-ref-26666259'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="315c241e-a8df-42ab-89a6-3f7410a214f9">Pneumonia, community-acquired, mild infection/step-down therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired (</b>
<i>
<b>M. pneumoniae, C.</b></i>
<i>
<b>pneumoniae, C. trachomatis</b></i>
<b>), </b>
<b>mild infection/step-down therapy</b>
<b>:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents with skeletal maturity: Oral: 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical (perioperative) prophylaxis (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 10 mg/kg within 120 minutes prior to surgical incision; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8d8d282f-9252-4467-b0ea-1d8a99bdedda">Tuberculosis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Drug-susceptible tuberculosis, pulmonary: </i>
<b>Note:</b> Use in combination with rifapentine, isoniazid, and pyrazinamide; see guidelines for regimen details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35202353','lexi-content-ref-35404556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35202353','lexi-content-ref-35404556'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents, weighing ≥40 kg: Oral: 400 mg once daily for 17 weeks (119 total doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35202353','lexi-content-ref-33951360','lexi-content-ref-35404556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35202353','lexi-content-ref-33951360','lexi-content-ref-35404556'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Drug-resistant tuberculosis</i>
<i>:</i>
<b>Note:</b> Use as part of an appropriate combination regimen; consult current guidelines for detailed information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-35404556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-35404556'])">Ref</a></span>). Pharmacokinetic studies suggest that higher doses may be necessary in pediatric patients to achieve target concentrations, but doses higher than 15 mg/kg/dose every 24 hours require further evaluation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34286843','lexi-content-ref-27742641','lexi-content-ref-25362206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34286843','lexi-content-ref-27742641','lexi-content-ref-25362206'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Oral, IV: 10 to 15 mg/kg/dose every 24 hours; usual maximum dose: 400 mg/dose; higher maximum doses (600 or 800 mg) may be used with higher minimum inhibitory concentrations (MICs) or in cases of malabsorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-34286843','lexi-content-ref-35404556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-34286843','lexi-content-ref-35404556'])">Ref</a></span>). Duration of therapy should be individualized based on patient-specific factors (eg, extent of disease, rapidity of culture conversion, clinical response, and toxicity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159485"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no pediatric specific recommendations. Based on experience in adult patients, no dosage adjustment necessary. Poorly dialyzed (&lt;10%); no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).</p></div>
<div class="block dohp drugH1Div" id="F51159486"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no pediatric specific recommendations. Based on experience in adult patients, no dosage adjustment necessary; however, use with caution; metabolic disturbances associated with hepatic insufficiency may lead to QT prolongation.</p></div>
<div class="block doa drugH1Div" id="F9348067"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9845" href="/d/html/9845.html" rel="external">see "Moxifloxacin (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inhalational (postexposure prophylaxis) (alternative agent):</i>
<b>Oral:</b> 400 mg once daily; duration depends on anthrax vaccine status and series completion, age, immune status, and pregnancy/breastfeeding status. For those who have not previously received an anthrax vaccine, duration ranges from 42 to 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>). Some experts favor longer durations of prophylaxis (eg, total of 3 to 4 months) for patients who are immunocompromised or remain unvaccinated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wilson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wilson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Anthrax vaccine should also be administered to exposed individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290','lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290','lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous (without systemic involvement), treatment:</i>
<b>Oral:</b> 400 mg once daily; duration is 60 days following a biological weapon-related event and 7 to 10 days after naturally acquired infection. <b>Note: </b>Treat patients with extensive edema or cutaneous lesions of the head or neck with a parenteral regimen recommended for systemic involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic (with or without meningitis), treatment (alternative agent):</i>
<b>IV:</b> 400 mg once daily as part of an appropriate combination regimen for ≥2 to 3 weeks or until clinically stable, whichever is longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Antitoxin should also be administered for patients with suspected systemic anthrax. Following the course of IV combination therapy for systemic anthrax infection (including meningitis), patients exposed to aerosolized spores require oral monotherapy to complete a total antimicrobial course of 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf0996fd-b1e3-4d3a-a9a0-7f24593cec52">Bite wound infection, prophylaxis of high-risk bite or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, prophylaxis of high-risk bite or treatment (animal or human bite) (alternative agent for patients who cannot receive beta-lactams) (off-label use):</b>
<b>Oral, IV:</b> 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>). For prophylaxis, duration is 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>); for treatment of established infection, duration is typically 5 to 14 days and varies based on clinical response and patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2020a','lexi-content-ref-Baddour.2020b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2020a','lexi-content-ref-Baddour.2020b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Some experts reserve for patients who have risk factors for poor outcomes (eg, ≥65 years of age, FEV<sub>1</sub> &lt;50% predicted, frequent exacerbations, major comorbidities), but are at low risk of <i>Pseudomonas</i> infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sethi.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sethi.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 400 mg once daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1','lexi-content-ref-22135277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1','lexi-content-ref-22135277'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c82d3ece-50d0-49c2-ae32-3a2c16f1d66e">Diabetic foot infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection (alternative agent for patients who cannot receive beta-lactams) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients at low risk for <i>Pseudomonas</i>
<i> aeruginosa </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Weintrob.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Weintrob.2020'])">Ref</a></span>)<i>.</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 400 mg once daily; for moderate to severe infections, use as part of an appropriate combination regimen<i>.</i> Duration of therapy should be tailored to individual clinical circumstances. Most patients with infection limited to skin and soft tissue respond to 1 to 2 weeks of therapy; for infections requiring surgical debridement, duration is usually 2 to 4 weeks in the absence of osteomyelitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-17553812','lexi-content-ref-19768381','lexi-content-ref-Weintrob.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-17553812','lexi-content-ref-19768381','lexi-content-ref-Weintrob.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9474c76-c81a-48ef-b80f-72ce1a0e25f5">Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure (alternative agent)</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Some experts avoid moxifloxacin due to high <i>Bacteroides</i> spp. resistance rates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2020'])">Ref</a></span>). Reserve for patients who are intolerant to both beta-lactams and metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pemberton.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pemberton.2020'])">Ref</a></span>). Empiric oral regimens may be appropriate for patients with mild to moderate infection. Other patients may be switched from IV to oral therapy at the same dose when clinically improved and able to tolerate an oral diet (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573','lexi-content-ref-20034345'])">Ref</a></span>). For acute diverticulitis, some experts suggest deferring antibiotics in otherwise healthy patients who are immunocompetent with mild disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26453777','lexi-content-ref-30664553','lexi-content-ref-34183510','lexi-content-ref-28719679','lexi-content-ref-28085573','lexi-content-ref-32073652']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26453777','lexi-content-ref-30664553','lexi-content-ref-34183510','lexi-content-ref-28719679','lexi-content-ref-28085573','lexi-content-ref-32073652'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 400 mg once daily. Duration of therapy is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2020','lexi-content-ref-Pemberton.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2020','lexi-content-ref-Pemberton.2020'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Routine use of fluoroquinolones is not recommended. Reserve for patients with severe allergy that precludes use of beta-lactams or carbapenems, or for resistant organisms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 400 mg once daily, often as part of an appropriate combination regimen. Treatment duration is 7 to 21 days, depending on causative pathogen(s) and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="82298537-4267-465e-af3a-ae742175b11c">
<i>Mycoplasma hominis</i> and <i>Ureaplasma</i> extragenital infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Mycoplasma hominis </i>and <i>Ureaplasma </i>extragenital infections: Oral, IV:</b> 400 mg once daily; for patients who are immunocompromised, some experts recommend combination therapy with doxycycline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25491170','lexi-content-ref-Waites.2020','lexi-content-ref-30642271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25491170','lexi-content-ref-Waites.2020','lexi-content-ref-30642271'])">Ref</a></span>). Duration of therapy varies depending on disease severity, site of infection, patient immune status, and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Waites.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Waites.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebce2e15-5575-4944-a590-3bb61b8252c0">Neutropenic fever, empiric therapy for low-risk patients with cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, empiric therapy for low-risk patients with cancer (eg, Multinational Association of Supportive Care in Cancer [MASCC] score ≥21) (alternative agent for patients who cannot receive beta-lactams) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid in patients who have received fluoroquinolone prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30179565','lexi-content-ref-Bow.2020','lexi-content-ref-21258094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30179565','lexi-content-ref-Bow.2020','lexi-content-ref-21258094'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 mg once daily; continue until fever and neutropenia have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bow.2020','lexi-content-ref-23358983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bow.2020','lexi-content-ref-23358983'])">Ref</a></span>). Administer first dose in the health care setting (after blood cultures are drawn); observe patient for ≥4 hours before discharge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30179565','lexi-content-ref-21258094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30179565','lexi-content-ref-21258094'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d4cf660-fc6c-4182-9e8b-10ee80fcb30b">Plague</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague (<i>Y. pestis</i>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis:</i>
<b>Oral:</b> 400 mg once daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i>
<b>Oral, IV:</b> 400 mg once daily for 7 to 14 days and for at least a few days after clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Stout.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Stout.1'])">Ref</a></span>). For plague meningitis, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75417c43-3c61-4fe2-a9af-58d21cc0cc97">Pneumonia, community-acquired, outpatients with comorbidities and inpatients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired, outpatients with comorbidities and inpatients (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Some experts reserve fluoroquinolones for patients who cannot take other preferred regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-File.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-File.2020'])">Ref</a></span>). Avoid use in patients with risk factors for <i>P. aeruginosa </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-File.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-File.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 400 mg once daily. For inpatients with severe pneumonia or risk factors for methicillin-resistant <i>Staphylococcus aureus</i>, use as part of an appropriate combination regimen. Duration is for a minimum of 5 days; patients should be clinically stable with normal vital signs prior to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-File.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-File.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832968','lexi-content-ref-26785402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832968','lexi-content-ref-26785402'])">Ref</a></span>). Due to risks associated with use, reserve fluoroquinolones for those who have no alternative treatment options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 mg once daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8597b7bf-d38b-46ed-ae30-27103563bc5c">Sexually transmitted infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycoplasma genitalium:</i>
<b>Oral:</b> 400 mg once daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-31629365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-31629365'])">Ref</a></span>). Some experts recommend preceding this with a course of doxycycline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pelvic inflammatory disease, outpatient therapy, mild to moderate disease (alternative agent):</i>
<b>Note:</b> Reserve for patients who cannot use first-line options, are at low risk for fluoroquinolone-resistant <i>Neisseria gonorrhoeae</i> (eg, prevalence is &lt;5% in the location where the infection was acquired), and likely to follow-up (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Wiesenfeld.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Wiesenfeld.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 mg once daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (alternative agent for patients who cannot receive beta-lactams):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for polymicrobial (including anaerobes) infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20876627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20876627'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis (alternative agent for hysterectomy or pelvic reconstruction procedures in patients </b>
<b>who cannot receive beta-lactams</b>
<b>) (off-label use):</b>
<b>IV:</b> 400 mg within 120 minutes prior to surgical incision in combination with other appropriate antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981','lexi-content-ref-Mann.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981','lexi-content-ref-Mann.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d0b676d-a613-433a-bb9c-e1e5e5a97c58">Tuberculosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Expert consultation for optimal regimen and duration of treatment is advised.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Drug-susceptible tuberculosis: </i>
<b>Oral, IV:</b> 400 mg once daily in combination with additional appropriate antituberculosis agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-35202353','lexi-content-ref-33951360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-35202353','lexi-content-ref-33951360'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">4-month rifapentine-moxifloxacin-based regimen: Intensive phase: Once daily rifapentine, moxifloxacin, isoniazid, and pyrazinamide for 8 weeks (56 doses), followed by a continuation phase of once daily rifapentine, moxifloxacin, and isoniazid for 9 weeks (63 doses). In the clinical trial, ≥5 doses/week were given by directly observed therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33951360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33951360'])">Ref</a></span>). <b>Note:</b> Reserve this regimen for patients ≥40 kg with pulmonary tuberculosis who are not pregnant or breastfeeding; for patients with HIV, only use if CD4 count ≥100 cells/mm<sup>3</sup> and in patients on an efavirenz-based antiretroviral regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35202353','lexi-content-ref-33951360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35202353','lexi-content-ref-33951360'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Drug-resistant tuberculosis:</i>
<b>Oral, IV:</b> 400 mg once daily in combination with additional appropriate antituberculosis agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908'])">Ref</a></span>); doses of 600 or 800 mg once daily have been used in select cases (eg, elevated minimum inhibitory concentration or malabsorption) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-30865791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-30865791'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration:</i> Individualize based on rapidity of culture conversion, extent of disease, and patient-specific factors, including clinical response and toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-27516382','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-27516382','lexi-content-ref-WHO.2'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed dose:</b> Administer as soon as possible if ≥8 hours until next scheduled dose; otherwise, wait until next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990578"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11874385','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11874385','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17555469','lexi-content-ref-28566592','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17555469','lexi-content-ref-28566592','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Poorly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15347636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15347636'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17699357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17699357'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987933"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary; however, use with caution in this patient population secondary to the risk of QT prolongation.</p></div>
<div class="block adr drugH1Div" id="F9347994"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (4%), dizziness (3%), insomnia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum glucose (≥2%), hyperchloremia (≥2%), increased serum albumin (≥2%), hypokalemia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (7%), diarrhea (6%), decreased amylase (≥2%), constipation (2%), vomiting (2%), abdominal pain (1% to 2%), dyspepsia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased basophils (≥2%), decreased red blood cells (≥2%), eosinopenia (≥2%), increased MCH (≥2%), increased neutrophils (≥2%), leukocytosis (≥2%), prolonged prothrombin time (≥2%), anemia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Decreased serum bilirubin (≥2%), increased serum bilirubin (≥2%), increased serum alanine aminotransferase (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Increased serum globulins (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased ionized serum calcium (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hypoxia (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal distention, abdominal distress, abnormal gait, abnormal hepatic function tests, agitation, agranulocytosis, allergic dermatitis, anaphylactic shock, anaphylaxis, angina pectoris, angioedema, anorexia, anxiety, aplastic anemia, arthralgia, asthenia, asthma, ataxia, atrial fibrillation, auditory impairment, back pain, blurred vision, bradycardia, bronchospasm, candidiasis, cardiac failure, chest discomfort, chest pain, chills, cholestatic hepatitis, <i>Clostridioides difficile</i> associated diarrhea, <i>Clostridioides difficile</i> colitis, confusion, deafness, decreased appetite, dehydration, delirium, depression, disorientation, disturbance in attention, drowsiness, dysesthesia, dysgeusia, dyspnea, dysuria, edema, eosinophilia, erythema of skin, exacerbation of myasthenia gravis, facial edema, facial pain, fatigue, flatulence, fungal infection, gastritis, gastroenteritis, gastroesophageal reflux disease, hallucination, hemolytic anemia, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hyperglycemia, hyperhidrosis, hyperlipidemia, hypersensitivity pneumonitis, hypersensitivity reaction, hypertension, hypoesthesia, hypoglycemia, hypotension, idiopathic intracranial hypertension, increased amylase, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased intracranial pressure, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum creatinine, increased serum lipase, increased serum triglycerides, increased uric acid, interstitial nephritis, jaundice, laryngeal edema, lethargy, leukopenia, limb pain, loss of consciousness, malaise, memory impairment, muscle spasm, musculoskeletal pain, myalgia, myasthenia, nervousness, neutropenia, nightmares, night sweats, pain, palpitations, pancytopenia, paranoid ideation, paresthesia, peripheral neuropathy (may be irreversible), pharyngeal edema, phlebitis, phototoxicity, polyneuropathy, prolonged partial thromboplastin time, prolonged QT interval on ECG, pruritus, renal failure syndrome, renal insufficiency, restlessness, rupture of tendon, seizure, serum sickness, skin photosensitivity, skin rash, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, syncope, tachycardia, tendinopathy, thrombocythemia, thrombocytopenia, thrombotic thrombocytopenic purpura, tingling sensation, tinnitus, torsades de pointes, toxic epidermal necrolysis, toxic psychosis, tremor, urticaria, vaginal infection, vasculitis, ventricular tachyarrhythmia, vertigo, vision loss, vulvovaginal pruritus, wheezing, xerostomia</p></div>
<div class="block coi drugH1Div" id="F9347991"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to moxifloxacin, other quinolone antibiotics, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F9347992"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered cardiac conduction: Fluoroquinolones may prolong QTc interval; avoid use in patients with known QTc prolongation, ventricular arrhythmias including torsades de pointes, proarrhythmic conditions (eg, clinically significant bradycardia, acute myocardial ischemia), uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).</p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic aneurysm and dissection: Fluoroquinolones have been associated with aortic aneurysm ruptures or dissection within 2 months following use, particularly in elderly patients. Fluoroquinolones should not be used in patients with a known history of aortic aneurysm or those at increased risk, including patients with peripheral atherosclerotic vascular diseases, hypertension, genetic disorders involving blood vessel changes (eg, Marfan syndrome, Ehlers-Danlos syndrome), and elderly patients, unless no other treatment options are available. Longer treatment duration (eg, &gt;14 days) may increase risk (Lee 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose regulation: Fluoroquinolones have been associated with disturbances in glucose regulation, including hyperglycemia and hypoglycemia. These events have occurred most often in elderly patients or patients receiving concomitant oral hypoglycemic agents or insulin. Severe cases of hypoglycemia, including coma and death, have been reported. Diabetic patients should be monitored closely for signs/symptoms of disordered glucose regulation. Discontinue if a hypoglycemic reaction occurs and immediately initiate appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Fulminant hepatitis potentially leading to liver failure (including fatalities) has been reported with use; patients should be advised to discontinue treatment and promptly report signs/ symptoms of hepatitis (eg, abdominal pain, jaundice, dark urine, pale stools).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may rarely cause moderate to severe phototoxicity reactions. Discontinue use if phototoxicity occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serious adverse reactions:<b> [US Boxed Warning]: Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that may occur together, including tendinopathy and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue moxifloxacin immediately and avoid use of fluoroquinolones in patients who experience any of these serious adverse reactions.</b> Patients of any age or without pre-existing risk factors have experienced these reactions; may occur within hours to weeks after initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">- CNS effects: Fluoroquinolones have been associated with an increased risk of CNS effects including seizures, increased intracranial pressure (including pseudotumor cerebri), lightheadedness, dizziness, and tremors. May occur following the first dose; discontinue immediately and avoid further use of fluoroquinolones in patients who experience these reactions. Use with caution in patients with known or suspected CNS disorder, or risk factors that may predispose to seizures or lower the seizure threshold.</p>
<p style="text-indent:-2em;margin-left:6em;">- Peripheral neuropathy: Fluoroquinolones have been associated with an increased risk of peripheral neuropathy; may occur soon after initiation of therapy and may be irreversible; discontinue if symptoms of sensory or sensorimotor neuropathy occur. Avoid use in patients who have previously experienced peripheral neuropathy.</p>
<p style="text-indent:-2em;margin-left:6em;">- Psychiatric reactions: Fluoroquinolones have been associated with an increased risk of psychiatric reactions, including toxic psychosis, hallucinations, or paranoia; may also cause nervousness, agitation, delirium, attention disturbances, insomnia, anxiety, nightmares, memory impairment, confusion, depression, and suicidal thoughts or actions. Use with caution in patients with a history of or risk factor for depression. Reactions may occur following the first dose; discontinue if reaction occurs and institute appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">- Tendinopathy/tendon rupture: Fluoroquinolones have been associated with an increased risk of tendinopathy and tendon rupture in all ages; risk may be increased with concurrent corticosteroids, solid organ transplant recipients, and in patients &gt;60 years of age, but has also occurred in patients without these risk factors. Rupture of the Achilles tendon has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps, hand) have also been reported. Inflammation and rupture may occur bilaterally. Cases have been reported within hours or days of initiation, and up to several months after discontinuation of therapy. Strenuous physical activity, renal failure, and previous tendon disorders may be independent risk factor for tendon rupture. Discontinue at first sign of tendon pain, swelling, inflammation or rupture. Avoid use in patients with a history of tendon disorders or who have experienced tendinopathy or tendon rupture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with significant bradycardia or acute myocardial ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; glucose regulation may be altered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with mild, moderate, or severe hepatic impairment or liver cirrhosis; may increase the risk of QT prolongation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: <b>[US Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis; avoid use in patients with known history of myasthenia gravis.</b> Cases of severe exacerbations, including the need for ventilatory support, and deaths have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal failure; may increase risk of tendon rupture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Adverse effects (eg, tendon rupture, QT changes) may be increased in elderly patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Hemolytic reactions may (rarely) occur with fluoroquinolone use in patients with G6PD deficiency (Luzzatto 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Efficacy of systemically administered moxifloxacin (oral, intravenous) have not been established in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b>[US Boxed Warning]:</b>
<b>Reserve use of moxifloxacin for treatment of acute bacterial sinusitis or acute bacterial exacerbation of chronic bronchitis for patients who have no alternative treatment options because of the risk of disabling and potentially serious adverse reactions (eg, tendinopathy and tendon rupture, peripheral neuropathy, CNS effects).</b></p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878751"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Arthropathy, or joint disease, has been observed in both animal and pediatric human studies following treatment with fluoroquinolone antibiotics, including moxifloxacin (Garazzino 2014; Patel 2016; Wirth 2018; manufacturer's labeling). In a randomized, double-blind study of pediatric patients (3 months to 17 years) receiving moxifloxacin for complicated intra-abdominal infection, a slightly higher incidence of musculoskeletal adverse events (including arthralgia) was observed in patients treated with moxifloxacin (4.3%; n=13/301) versus ertapenem and amoxicillin/clavulanate (3.3%; n=5/150). Arthralgia occurred in 9 (3%) moxifloxacin-treated patients and 1 (1.3%) ertapenem and amoxicillin/clavulanate-treated patient. None of the musculoskeletal adverse effects were considered to be related to either study medication; most events were mild and occurred 3 weeks to 1 year after receipt of medication, and all resolved by the end of the 5-year follow-up period (Wirth 2018; manufacturer's labeling). Arthropathy and arthralgias appear to resolve after discontinuation of treatment, with no long-term sequelae (Garazzino 2014; Patel 2016; Torres 2008; Wirth 2018). Though the true incidence is unknown, arthropathy and arthralgia are considered to be infrequent but potentially serious adverse reactions; higher doses and prolonged exposure likely increase risk (AAP [Jackson 2016]; Garazzino 2014; Patel 2016; Torres 2008).</p>
<p style="text-indent:0em;margin-top:2em;">Moxifloxacin may cause QT prolongation. In a double-blind, randomized trial, pediatric patients (age 3 months to &lt;18 years) receiving moxifloxacin for complicated intra-abdominal infections for a mean of 6.2 days IV and 4.4 days orally had a higher incidence of QT prolongation (overall: 9.3%; n=28/301; considered drug-related: 7%; n=21/301) when compared to patients receiving ertapenem and amoxicillin/clavulanate (2.7%; n=4/150; considered drug-related: 1.3%, n=2/150) (Wirth 2018). In a retrospective evaluation of 220 pediatric patients (age 8.5 months to 17.9 years) who received 300 courses of moxifloxacin (mean dose: &lt;40 kg: ~10 mg/kg; ≥40 kg: ~400 mg), ECG was performed during therapy in 85 courses. QTc prolongation was noted in 29 courses, with 18 (6%) attributed to moxifloxacin, occurring at a mean of 11 days (range: 1 to 62 days) after initiation. In 10 of the courses with QTc prolongation, moxifloxacin was used with concomitant QTc-prolonging agents (Dixit 2018). No cardiac events or clinical sequelae were reported in either study (Dixit 2018; Wirth 2018). Avoid use in patients with known QT prolongation, ventricular arrhythmias including torsades de pointes, proarrhythmic conditions (eg, clinically significant bradycardia, acute myocardial ischemia), or uncorrected hypokalemia and hypomagnesemia, and in patients concomitantly receiving drugs that prolong the QT interval (manufacturer's labeling).</p></div>
<div class="block foc drugH1Div" id="F9348115"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avelox: 400 mg/250 mL (250 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg/250 mL (250 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg</p></div>
<div class="block geq drugH1Div" id="F9347902"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F9348117"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Moxifloxacin HCl in NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg/250 mL (per mL): $0.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Moxifloxacin HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg/250 mL (per mL): $0.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Moxifloxacin HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $27.19 - $27.23</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869436"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avelox: 400-0.8 MG/250ML-% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg/250 mL (250 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg</p></div>
<div class="block exp drugH1Div" id="F10806359"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">20 mg/mL Oral Suspension:</p>
<p style="text-indent:-2em;margin-left:4em;">A 20 mg/mL oral suspension may be made using tablets. Crush three 400 mg tablets and reduce to a fine powder. Carefully sieve powder from enteric-coating remnants to improve pharmaceutical elegance. Add a small amount of a 1:1 mixture of Ora-Plus and Ora-Sweet or Ora-Sweet SF and mix to a uniform paste; mix while adding the vehicle in geometric proportions to <b>almost</b> 60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label "shake well." Stable 90 days at room temperature.</p>
<div class="reference">Hutchinson DJ, Johnson CE, Klein KC. Stability of extemporaneously prepared moxifloxacin oral suspensions. <i>Am J Health Syst Pharm</i>. 2009;66(7):665-667.<span class="pubmed-id">19299374</span></div>
</div>
<div class="block adip drugH1Div" id="F53570189"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Avelox IV infusion (premixed in sodium chloride 0.8%) contains sodium 34.2 mEq (~787 mg)/250 mL.</p></div>
<div class="block admp drugH1Div" id="F52614382"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer using the premix solution (1.6 mg/mL) over 60 minutes; do not infuse by rapid or bolus IV infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35284983','lexi-content-ref-30681729','lexi-content-ref-29356761','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35284983','lexi-content-ref-30681729','lexi-content-ref-29356761','lexi-content-ref-Manu.1'])">Ref</a></span>). When the same IV line is used for sequential infusion of other medications, flush line with a compatible solution (eg, NS, D5W, D10W, LR) before and after infusing moxifloxacin.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to meals. Administer 4 hours before or 8 hours after products containing magnesium, aluminum, iron, or zinc, including antacids, sucralfate, multivitamins, and didanosine (buffered tablets for oral suspension or the pediatric powder for oral solution). Tablets may be crushed and suspended in water for immediate administration; however, crushed tablets have a bitter taste and may not be tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25362206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25362206'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Missed dose: Administer as soon as possible if ≥8 hours until next scheduled dose; otherwise, wait until next scheduled dose.</p></div>
<div class="block adm drugH1Div" id="F9348080"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to meals. Administer at least 4 hours before or 8 hours after products containing magnesium, aluminum, iron, or zinc, including antacids, sucralfate, multivitamins, and didanosine (buffered tablets for oral suspension or the pediatric powder for oral solution).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 60 minutes; do not infuse by rapid or bolus intravenous infusion.</p></div>
<div class="block sts drugH1Div" id="F9348031"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Premixed in freeflex bags: Store at 20°C to 25°C (68°F to 77°F); do not refrigerate. Retain in overwrap to protect from light; use immediately once removed from the overwrap.</p>
<p style="text-indent:-2em;margin-left:2em;">Premixed in sodium chloride 0.8%: Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Do not refrigerate infusion solution; discard unused portion.</p></div>
<div class="block meg drugH1Div" id="F9347836"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Avelox: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F021085s066%2C021277s062lbl.pdf%23page%3D33&amp;token=ESvJ%2B7pUrKlCz1gcbRfO80e5ZfCFgrmyq9hxWM7eXdRkyctgBAlWiJLykhff4O7iDPEBGhc4LxqXNTabMYZOqNWnokiDbJLJ%2Bbbadrm6LCAIL1w%2FqJMIKEIk0EDq0jNP&amp;TOPIC_ID=113351" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021085s066,021277s062lbl.pdf#page=33</a></p>
<p style="text-indent:-2em;margin-left:4em;">Moxifloxacin IV solution: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F205572s006lbl.pdf%23page%3D49&amp;token=in4i%2FmoTznyuIE4SljLjybkgUVWC7m5srTvLVJmbi7D%2B%2Fpftg0T4o6ffHP4942rEmPNs%2F9Wb95oji%2Fs3EjPq65hobTcYc7ZYdD3yV2maYSUJEvwgq6DwTaWrInGadG8P&amp;TOPIC_ID=113351" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205572s006lbl.pdf#page=49</a></p></div>
<div class="block usep drugH1Div" id="F53570664"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of the following infections caused by susceptible bacteria: community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, acute bacterial sinusitis, skin and soft tissue infections, complicated intra-abdominal infections; treatment and prophylaxis of plague (<i>Yersinia pestis</i>) (All indications: FDA approved adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Fluoroquinolones should not typically be used as first-line therapy due to their adverse effect profile and risk of development of bacterial resistance. Only use in situations when there is no safe and effective substitute available (eg, drug resistance, allergy) or when oral fluoroquinolone therapy provides a reasonable alternative to parenteral therapy (AAP [Jackson 2016]; Bradley 2021; Patel 2016; <i>Red Book </i>[AAP 2021]).</p></div>
<div class="block mst drugH1Div" id="F9347835"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Avelox may be confused with Avonex</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299729"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9347999"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Quinolones may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: May decrease the absorption of Moxifloxacin (Systemic). Management: Administer moxifloxacin at least 4 hours before or 8 hours after aluminum hydroxide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the cardiotoxic effect of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Charcoal, Activated: May decrease the serum concentration of Moxifloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of Delamanid. Management: Avoid concomitant use of delamanid and quinolone antibiotics if possible. If coadministration is considered to be unavoidable, frequent monitoring of electrocardiograms throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: May enhance the hyperglycemic effect of Moxifloxacin (Systemic). Hydroxychloroquine may enhance the hypoglycemic effect of Moxifloxacin (Systemic). Hydroxychloroquine may enhance the QTc-prolonging effect of Moxifloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, oflox-, peflox, or nalidixic acid) oral iron.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar/enox-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe/enox-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Moxifloxacin (Systemic) may enhance the arrhythmogenic effect of Mequitazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May enhance the cardiotoxic effect of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Administer oral quinolones at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (ie, calcium, iron, magnesium, selenium, zinc). Monitor for decreased quinolone efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Administer oral quinolones at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (ie, calcium, iron, magnesium, selenium, zinc). Monitor for decreased therapeutic effects of quinolones.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Quinolones. Management: Give oral quinolones at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Moxifloxacin (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of other QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Moxifloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the serum concentration of Quinolones. Management: Avoid concurrent administration of quinolones and sucralfate to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F9348003"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Absorption is not affected by administration with a high-fat meal or yogurt.</p></div>
<div class="block dic drugH1Div" id="F9348079"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Premixed in freeflex bags contains sodium ~52.5 mEq (~1,207 mg)/250 mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Premixed in sodium chloride 0.8% contains sodium ~34.2 mEq (~787 mg)/250 mL.</p></div>
<div class="block pri drugH1Div" id="F9347985"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Moxifloxacin crosses the placenta (Ozyüncü 2010a; Ozyüncü 2010b).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of moxifloxacin may be altered. Dose adjustment was not needed in 1 woman treated with moxifloxacin for multidrug-resistant tuberculosis (Nemutlu 2010; van Kampenhout 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Moxifloxacin is used off label for the treatment of drug-resistant tuberculosis. Tuberculosis (TB) disease (active TB) is associated with adverse fetal outcomes, including intrauterine growth restriction, low birth weight, preterm birth, and perinatal death (Esmail 2018; Miele 2020), as well as adverse maternal outcomes, including increased risks for anemia and cesarean delivery. Placental transmission may rarely occur with active maternal disease (Miele 2020). Data are limited for use of second-line drugs in pregnancy (ie, fluroquinolones). Individualized regimens should be utilized to treat multidrug-resistant TB in pregnant patients; evidence to support a specific regimen is not available. Based on susceptibility testing, moxifloxacin may be used to treat multidrug-resistant TB during pregnancy when needed (ATS/CDC/ERS/IDSA [Nahid 2019]; HHS [OI adult 2020]; WHO 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Moxifloxacin is used off-label to reduce the incidence or disease progression of inhalational anthrax (postexposure). Untreated anthrax infection during pregnancy is associated with preterm labor, fetal distress, and fetal loss. However, moxifloxacin is not the preferred fluoroquinolone for the prophylaxis or treatment of anthrax in pregnant and postpartum patients (Meaney-Delman 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated plague (<i>Y. pestis</i>) infection in pregnant patients may result in hemorrhage (including postpartum hemorrhage), maternal and fetal death, preterm birth, and stillbirth. Limited data suggest maternal-fetal transmission of <i>Y. pestis</i> can occur if not treated. Pregnant patients should be treated for <i>Y. pestis</i>; parenteral antibiotics are preferred for initial treatment when otherwise appropriate. Moxifloxacin is an alternative fluoroquinolone recommended for use (in combination with an aminoglycoside) for treating pregnant patients with bubonic, pharyngeal, pneumonic, or septicemic plague. Recommendations for treating pregnant patients with plague meningitis are the same as in nonpregnant patients. Moxifloxacin may also be used as an alternative antibiotic for pre- and postexposure prophylaxis in pregnant patients exposed to <i>Y. pestis </i>(CDC [Nelson 2021]).</p></div>
<div class="block mopp drugH1Div" id="F53570663"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC and LFTs with prolonged use (Dixit 2018), ECG (eg, baseline and at steady state or after 7 to 10 days of therapy; monitor more frequently in patients with liver cirrhosis or concomitant QTc-prolonging medications; for tuberculosis treatment, consider monitoring at baseline, at 2 weeks and 4 weeks after initiation, and every 4 weeks thereafter) (Dixit 2018; Khatib 2021; WHO 2022; manufacturer's labeling). Monitor for signs and symptoms of joint or tendon pain, sensory pain (eg, pain, burning, tingling, numbness, weakness, alteration of senses), and CNS effects (eg, nervousness, agitation, insomnia, anxiety, dizziness, tremors).</p></div>
<div class="block rerp drugH1Div" id="F53570126"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Regular therapeutic drug monitoring is not recommended; may be considered when treatment response is poor, if malabsorption is known or suspected, if drug-drug interactions exist, or if dose is uncertain (ATS/CDC/ERS/IDSA [Nahid 2019]; BTS [Haworth 2017]; CFF/ECFS [Floto 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">Nontuberculous mycobacterial infections: Peak (2 hours postdose): 2.5 to 4 mg/L (BTS [Haworth 2017]).</p>
<p style="text-indent:-2em;margin-left:2em;">Tuberculosis: Pediatric patients: Peak (2 hours postdose): 3 to 5 mg/L (ATS/CDC/IDSA [Nahid 2016]).</p></div>
<div class="block pha drugH1Div" id="F9348034"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Moxifloxacin is a DNA gyrase inhibitor, and also inhibits topoisomerase IV. DNA gyrase (topoisomerase II) is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; inhibition is bactericidal.</p></div>
<div class="block phk drugH1Div" id="F9348036"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed; not affected by high-fat meal or yogurt.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Tissue concentrations often exceed plasma concentrations in respiratory tissues, alveolar macrophages, abdominal tissues/fluids, uterine tissue (endometrium, myometrium), and sinus tissues.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &gt;3 months of age, children, and adolescents ≤13 years of age: ~1.5 to 2.3 L/kg (Stass 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 1.7 to 2.7 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~30% to 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (~52% of dose) via glucuronide (~14%) and sulfate (~38%) conjugation.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients: Single dose: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &gt;3 months of age and children &lt;2 years of age: IV: ~5.9 to 6.8 hours (Stass 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 to &lt;6 years of age: ~5.7 to 6 hours (Stass 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years of age and adolescents ≤13 years of age: ~6.2 to 7.9 hours (Stass 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Single dose: Oral: ~11.5 to 15.6 hours; IV: 8.2 to 15.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Children ≥7 years and adolescents ≤15 years: Whole tablet: Median: 3 hours (range: 1 to 8 hours); Crushed tablet: Median: 1 hour (range: 1 to 2 hours) (Thee 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as unchanged drug [20%] and glucuronide conjugates); feces (as unchanged drug [25%] and sulfate conjugates).</p></div>
<div class="block phksp drugH1Div" id="F54994946"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Concentration dependent: Associated with AUC<sub>24</sub>/minimum inhibitory concentration (MIC) and C<sub>max</sub> (peak)/MIC.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Pathogen specific:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Gram negative organisms: AUC<sub>24</sub>/MIC ≥100 to 125 (Abdul-Aziz 2020; Odenholt 2006; Rodvold 2001) or C<sub>max</sub>/MIC ≥10 (Odenholt 2006; Rodvold 2001).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>S. pneumoniae</i>: AUC<sub>24</sub>/MIC ≥30 (bactericidal) (Ambrose 2001; Garrison 2003; Lacy 1999; Lister 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in patients with normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">AUC<sub>24</sub>:</p>
<p style="text-indent:-2em;margin-left:8em;">IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Pediatric patients with suspected or proven infection, single dose (geometric mean):</p>
<p style="text-indent:-2em;margin-left:12em;">Infants &gt;3 months of age and children &lt;2 years of age: 9 mg/kg: 25.5 mg•hour/L (Stass 2019).</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥2 to &lt;6 years of age: 7 mg/kg: 28.2 mg•hour/L (Stass 2019).</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥6 years of age and adolescents ≤13 years of age: 5 mg/kg: 19.7 mg•hour/L (Stass 2019).</p>
<p style="text-indent:-2em;margin-left:10em;">Adults: 400 mg once daily, multiple dose: 38 ± 4.7 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:8em;">Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">Children and adolescents 7 to 15 years of age: 10 mg/kg, steady state: median 23.3 mg•hour/L (range 19.2 to 42.3 mg•hour/L) (Thee 2015).</p>
<p style="text-indent:-2em;margin-left:10em;">Adults: 400 mg once daily, multiple dose: 48 ± 2.7 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:6em;">C<sub>max </sub>(peak):</p>
<p style="text-indent:-2em;margin-left:8em;">IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Pediatric patients with suspected or proven infection, single dose (geometric mean):</p>
<p style="text-indent:-2em;margin-left:12em;">Infants &gt;3 months of age and children &lt;2 years of age: 9 mg/kg: 5.3 mg/L (Stass 2019).</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥2 to &lt;6 years of age: 7 mg/kg: 6.5 mg/L (Stass 2019).</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥6 years of age and adolescents ≤13 years of age: 5 mg/kg: 3.2 mg/L (Stass 2019).</p>
<p style="text-indent:-2em;margin-left:10em;">Adults: 400 mg once daily, multiple dose: 4.2± 0.8 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">Children and adolescents 7 to 15 years of age: 10 mg/kg, steady state: median 3.08 mg/L (range: 2.85 to 3.82 mg/L) (Thee 2015).</p>
<p style="text-indent:-2em;margin-left:10em;">Adults: 400 mg once daily, multiple dose: 4.5 ± 0.5 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Bacterial killing continues after moxifloxacin concentration falls below the MIC of targeted pathogen and varies based on the organism; generally, 1 to 3 hours (Boswell 1999).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961992"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Arox | Avalox | Elfonis | Evaflox | Genlox | Gyraquin | Moxican | Moxiflox | Moxiquin | Moxive | Moxiwar | Muxava | Rt-mox | Xflox</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxibase | Octegra</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Actira | Avelox | Moxifloxacin +pharma | Moxifloxacin 1A pharma | Moxifloxacin acino | Moxifloxacin inres | Moxifloxacin kabi | Moxifloxacin krka | Moxifloxacin ratiopharm | Moxifloxacin sandoz | Moxifloxacin stada | Octegra</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxifloxacin | Moxifloxacin apotex | Moxifloxacin kabi</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cubimox | Floromox | Floxalone | Iventi | Maximox | Moxibac | Moxiflox | Moxigen | Moxquin | Odycin | Optimox | Respamox | Revalon | Topmox | Topomox | Visomox | Zydus</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxifloxacin | Moxifloxacin ab | Moxifloxacin sandoz | Moxifloxacin teva | Moxifloxacine eg | Moxifloxacine fresenius kabi | Proflox</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Micromox | Staxom</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Cimocinox | Erelan | Kimoks | Moloxin | Moxi | Moxiquin | Moxistad</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Avalox | Cloridrato de moxifloxacino | Moclazom | Moxibacten | Moxicris | Neumosin | Praiva | Promira</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Avalox | Moxifloxacin actavis | Moxifloxacin mepha | Moxifloxacin sandoz | Moxifloxacin spirig hc</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Avelox | M flox | Micromox | Staxom</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Imix | Moxaval | Moxicino | Moxifloxacino | Octegra</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxifloxacin hydrochloride and sodium chloride</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Bacterol | Beomax | Floxanar | Flurox | Fluxinol | Mofloxin | Motico | Moxfacin | Moxifen | Moxifloxacina | Moxifloxacino | Moxis | Oxifled | Pixiriv | Quinomax | Ucos | Urinex | Uropirin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moflaxa | Moxifloxacin aurovitas | Moxifloxacin kabi | Moxifloxacin olikla</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Actimax | Actira | Avalox | Avelox | Moxifloxacin | Moxifloxacin 1 a pharma | Moxifloxacin abz | Moxifloxacin actavis | Moxifloxacin al | Moxifloxacin aristo | Moxifloxacin aurobindo | Moxifloxacin hec pharm | Moxifloxacin hexal | Moxifloxacin holsten | Moxifloxacin inresa | Moxifloxacin kabi | Moxifloxacin micro | Moxifloxacin noridem | Moxifloxacin puren | Moxifloxacin ratiopharm | Moxifloxacin stada | Moxifloxacin tillomed</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Moxiva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Etifloxina | Moxaval | Moximine | Moximuk</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Flovacil | Floxanar | Flukal | Flurox | Mofloxin | Moxaval | Moxifloxacino | Moxifloxacino la sante | Moxifloxacino mk | Moxital | Nexanti | Potenza | Quinomax</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Floxelan | Moflaxa</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Actimoxiflox | Advancrib | Avalox | Azgoflox | Delmoxa | Dolabactin | Floxepci | Fluroflox | Gastamoxacine | Idelox | Kinomoxi | Meramerix | Moflox | Mograflox | Moxacin | Moxavidex | Moxifl | Moxiflox | Moxifloxacin | Moxilabact | Moxitrix | Primoxizar | Quinofloxachem | Raspelocin | Rowamoxiflox | Shamsomox</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Abiox | Actira | Erelan | Moxifloxacino actavis | Moxifloxacino apotex | Moxifloxacino aurobindo | Moxifloxacino aurovitas | Moxifloxacino bluepharma | Moxifloxacino cinfa | Moxifloxacino kabi | Moxifloxacino kern pharma | Moxifloxacino krka | Moxifloxacino mylan | Moxifloxacino normon | Moxifloxacino pensa | Moxifloxacino qualigen | Moxifloxacino ratiopharm | Moxifloxacino sandoz | Moxifloxacino stada | Moxifloxacino teva | Moxifloxacino zentiva | Octegra | Proflox</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Floxsafe | Macflox | Mahaflox | Moxam | Moxifloxacin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxifloxacin Fresenius Kabi | Moxifloxacin krka | Moxifloxacin orion | Moxifloxacin sanoswiss | Moxifloxacin stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Izilox | Moxifloxacine arrow | Moxifloxacine biogaran | Moxifloxacine eg | Moxifloxacine krka | Moxifloxacine mylan | Moxifloxacine Sandoz</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxifloxacin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Mikrobiel | Moxifalon | Moxifalon T | Moxifloxacin aurobindo | Moxifloxacin vioser | Moxifloxacin/sandoz | Octegra | Oflokasin | Tamvelier</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Avelox</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moksacin | Moksifloksacin Alvogen | Moksifloksacin Double-E Pharma | Moksifloksacin PharmaS | Moloxin | Moxifloxacin kabi | Plivamox</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxibiot | Moxifloxacin actavis | Moxifloxacin kabi | Moxifloxacin onkogen | Moxifloxacin Q Pharma | Moxifloxacin ratiopharm | Moxifloxacin teva | Octegra</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Garena | Molcin | Moxifloxacin | Moximed | Moxivar | Moxivid | Mxn</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Avelox</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Megaxin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Floxsafe | Hixcin | M cin | Macflox | Mahaflox | Moxam | Moxicip | Moxidac | Moxif | Moxiflox | Moxigood | Moxigram | Moxilone | Moximac | Moximycin | Moxinic | Moxplore | Staxom</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Actira | Avalox | Moxifloxacina aurobindo | Moxifloxacina krka | Moxifloxacina Pensa | Octegra</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Avalox | Avaquin | Avores | Mofloxine | Muxava</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Avelox</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Floxsafe | M flox | Mahaflox | Maxim | Micromox | Mofloxine | Molox | Moxaf | Moxeque | Moxi bio | Moxicip | Moxidoc | Moxifloxacin | Moxiget | Moxilon | Moxima | Moximac | Moxoft | Oxiloc | Plenmoxi | Staxom | Tamvelier | Zeebact</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Joyloxin | Jw moxifloxacin | Moroxacin | Moveloxin | Moxiflo | Moxiroc | Quinox | Remox | Rymox</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Avalox | Maxim | Muxava | Xflox</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Avalox | Evaflox | Loximed | Mofloxine | Moksefen</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Floxelan | Moflaxa | Moxifloxacin | Moxifloxacin krka</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxifloxacin apotex | Moxifloxacin ratiopharm | Moxifloxacine eg | Proflox</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Avalox | Avelox | Moloxin | Moxifloxacin sandoz</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Aquinex | Avelox | Modixa | Staxom | Xyflo | Zivlox | Zylax</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alloc | Avelox | Aveloxatil | Avestrep | Bancifar | Brofort | Crescrin | Degorbak | Dupeo | Esthipia | Incadix | Mosalinafe | Moxifloxacin | Moxifloxacina | Moxifloxacino | Pixiriv | Praiva | Zinolox 4G</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Flonoxin | Moxi | Moxifloxacin kabi | Moximac | Moxiwar</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Floxsafe | Macflox | Moxitab</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxifloxacine Actavis | Moxifloxacine fresenius kabi | Moxifloxacine Sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxifloxacin | Moxifloxacin aurovitas | Moxifloxacin sandoz</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxifloxacin kabi</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Flovacil | Floxitel | Mevafast | Moxcda | Moxflin | Moxifloxacino | Moxiliph | Praiva</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxiflax | Moxiflox | Xiflox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Acflox | Actimox | Ademox | Adloxin | Akxi | Aramox | Astron | Avelin | Avelon | Avelox | Averox | Axilent | Bactirol | Barimox | Benmox | Biofloxacin | Biomox | Cimox | Duramox | Em Flox | Fan c | Fluxaquin | Fotiflox | G mox | Gilmox | Glosiflox | Gt mox | Henazim | Hicox | Hiramox | Imox | Inmex | Inmox | Izilon | Kipra | Koxicin | Largimox | Lemox | Linzox | Locgin | M floxin | M floxsel | M oxin | Maflex | Maksifin | Maxlox | Maxon | Mebarg | Medmox | Meflox | Metromoxy | Microcid | Mionex | Mob | Mobact | Mobik | Mofest | Mofilox | Moflaxa | Moflex | Moflox | Mofloxen | Mofoxin | Moftab | Mogiz | Moksi | Molam | Molinza | Molox | Morax | Mosac | Mosic | Mox q | Moxacin | Moxan | Moxbay | Moxer | Moxeza | Moxi | Moxibact | Moxica | Moxicin | Moxicure | Moxidanz | Moxifar | Moxiflen | Moxifo | Moxifon | Moxiget | Moxila | Moxilet | Moxiline | Moxilis | Moxilox | Moximaf | Moximax | Moxina | Moxinor | Moxipro | Moxira | Moxirains | Moxirex | Moxisaf | Moxisrch | Moxistar | Moxitier | Moxiton | Moxitop | Moxitrum | Moxivant | Moxizak | Moxizon | Moxizyan | Moxox | Moxrik | Moxup | Moxy day | Moxycare | Moxyguf | Mozex | Mozter | Myflox | Myriva | Navilox | Neumox | Odimox | Oxaquin | Oxiloc | Oxizam | Palzic | Q mox | Raymox | Remox | Renoval | Rotamox | Rt-mox | Saimox | Santomox | Saymox | Scimox | Staxin | Twig | Ucit | Velmox | Veloxin | Winloxine | X gen | X lox | Xclent | Xefecta | Xitocin | Xmox | Zaflox | Zetamox | Zymox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Floxitrat | Moloxin | Moxifloxacin aurovitas | Moxinea</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Avelox abc | Moxifloxacin | Moxifloxacin HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxifloxacina aurobindo | Moxifloxacina Bluepharma | Moxifloxacina ciclum | Moxifloxacina krka | Moxifloxacina Mylan | Proflox</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Broncomicina | Isobiotic | Moxaval | Moxifloxacina la sante | Telxus</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Arox | Avalox | Avores | Demoxif | Mofloxine | Moxai | Moxiget | Moxiquin | Moxiwar | Muxava | Xflox</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Erelan | Kimoks | Moflaxa | Moxifloxacina aurobindo | Moxifloxacina kabi | Moxifloxacina rompharm</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alvelon mf | Aquamox | Avelox | Hinemox | Kimox | Megaflox | Moflaxia | Mogaflox | Moxiflo | Moxifloxacin | Moxifloxacin alvogen | Moxifloxacin Binergia | Moxifloxacin canon | Moxifloxacin ferein | Moxifloxacin solopharm | Moxifloxacin stada | Moxifloxacin TL | Moxifloxacine KGP | Moxigram | Moximac | Moxispenser | Moxistar | Plevilox | Simoflox</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Avalox | Avores | Flomocin | Maxim | Moxican | Moxiquin | Moxive</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moxifloxacin 2care4 | Moxifloxacin abacus medicine | Moxifloxacin Ebb | Moxifloxacin Fresenius Kabi | Moxifloxacin krka | Moxifloxacin orion | Moxifloxacin paranova | Rivomoxi</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moloxin | Moxifloxacin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Kimoks | Moksifloksacin kabi | Moksifloksacin stada | Moloxin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Moloxin | Moxifloxacin kabi</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Mofloxin | Svoz</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Moxifloxacine mylan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Atafloks | Avelox | Demoxif | Emesmox | Mofelox | Moksefen | Moksilox | Moksine | Moxacin | Moxai | Moxday | Moxhel | Moxicum | Moxifix | Moxifor | Moxitab | Moxitec | Multiflex moxiflex | Pitoxil | Pnemox | Turktipsan moksifloksasin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Floxsafe | Mofacin | Moflodal | Mosflow | Moxetero | Moxicin | Moxifloxacin | Moxifloxacin kabi</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Atovax | Avelox | Floxsafe | Maxicin | Moflaxa | Moxetero | Moxicum | Moxif | Moxifloxacin | Moxifloxacin sandoz | Moxifloxacin vioser | Moxifloxacin vista | Moxiftor | Moximac | Moxin | Moxivar | Tevalox | Timoxy</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Floxsafe | M flox | Micromox | Moksefen | Moxaf | Moxam | Moxicip | Moxidoc | Moxiflox | Moximac</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Cifloxim | Praiva</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Avelox | Axokine | Megamox | Moflox | Moxen | Moxifloxacina | Moximycin | Moxval</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Biviflox | Eftimoxin | Moloxcin | Praxinstad | Rvmoxi</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Austell moxifloxacin | Avebact | Avelon | Avoxa | DRL Moxifloxacin | Floxave | Litares | Mofloxx | Moxibay | Moxifloxacin | Moxifloxacin ascendis | Moxifloxacin macleods | Numoxx | Oxifled</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">M flox | Moxicip | Moxifloxacin | Oxifled</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. <i>Intensive Care Med.</i> 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11557471">
<a name="11557471"></a>Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. <i>Antimicrob Agents Chemother</i>. 2001;45(10):2793-2797. doi:10.1128/AAC.45.10.2793-2797.2001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/11557471/pubmed" id="11557471" target="_blank">11557471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NelsonPed.1">
<a name="NelsonPed.1"></a>Antibiotic therapy according to clinical syndromes. In: Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021:chap 1.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avelox.1">
<a name="Avelox.1"></a>Avelox (moxifloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2020a">
<a name="Baddour.2020a"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 25, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2020b">
<a name="Baddour.2020b"></a>Baddour LM, Harper M. Human bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ESCRS.2013">
<a name="ESCRS.2013"></a>Barry P, Corcoves L, Gardner S. <i>ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery: Data, Dilemmas and Conclusions</i>. European Society of Cataract and Refractive Surgeons; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.2020">
<a name="Barshak.2020"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25537875">
<a name="25537875"></a>Bissessor M, Tabrizi SN, Twin J, et al. Macrolide resistance and azithromycin failure in a <i>Mycoplasma genitalium</i>-infected cohort and response of azithromycin failures to alternative antibiotic regimens. <i>Clin Infect Dis.</i> 2015;60(8):1228-1236. doi:10.1093/cid/ciu1162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/25537875/pubmed" id="25537875" target="_blank">25537875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10382875">
<a name="10382875"></a>Boswell FJ, Andrews JM, Wise R, Dalhoff A. Bactericidal properties of moxifloxacin and post-antibiotic effect.<i> J Antimicrob Chemother.</i> 1999;(43 suppl B):43-49. doi:10.1093/jac/43.suppl_2.43<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/10382875/pubmed" id="10382875" target="_blank">10382875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bow.2020">
<a name="Bow.2020"></a>Bow E. Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834290">
<a name="31834290"></a>Bower WA, Schiffer J, Atmar RL, et al; ACIP Anthrax Vaccine Work Group. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. <i>MMWR Recomm Rep</i>. 2019;68(4):1-14. doi:10.15585/mmwr.rr6804a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/31834290/pubmed" id="31834290" target="_blank">31834290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2011;53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777226">
<a name="24777226"></a>Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-1436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/24777226/pubmed" id="24777226" target="_blank">24777226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18978939">
<a name="18978939"></a>Bradshaw CS, Chen MY, Fairley CK. Persistence of <i>Mycoplasma genitalium</i> following azithromycin therapy. <i>PLoS One</i>. 2008;3(11):e3618.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/18978939/pubmed" id="18978939" target="_blank">18978939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283. doi:10.2146/ajhp120568<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35202353">
<a name="35202353"></a>Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - United States, 2022. <i>MMWR Morb Mortal Wkly Rep</i>. 2022;71(8):285-289. doi:10.15585/mmwr.mm7108a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/35202353/pubmed" id="35202353" target="_blank">35202353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>Centers for Disease Control and Prevention (CDC). Plague. Resources for Clinicians. <a href="https://www.cdc.gov/plague/healthcare/clinicians.html" target="_blank">https://www.cdc.gov/plague/healthcare/clinicians.html</a>. Updated February 10, 2020. Accessed August 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12836625">
<a name="12836625"></a>Centers for Disease Control and Prevention (CDC). Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. <i>MMWR Recomm Rep</i>. 2003;52(RR-11):3-5. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/12836625/pubmed" id="12836625" target="_blank">12836625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112. doi:10.1093/cid/cir1043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17699357">
<a name="17699357"></a>Czock D, Hüsig-Linde C, Langhoff A, et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. <i>Clin J Am Soc Nephrol.</i> 2006;1(6):1263-1268. doi:10.2215/CJN.01840506<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/17699357/pubmed" id="17699357" target="_blank">17699357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30664553">
<a name="30664553"></a>Desai M, Fathallah J, Nutalapati V, Saligram S. Antibiotics versus no antibiotics for acute uncomplicated diverticulitis: a systematic review and meta-analysis. <i>Dis Colon Rectum</i>. 2019;62(8):1005-1012. doi:10.1097/DCR.0000000000001324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/30664553/pubmed" id="30664553" target="_blank">30664553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29939314">
<a name="29939314"></a>Dixit A, Karandikar MV, Jones S, Nakamura MM. Safety and tolerability of moxifloxacin in children. <i>J Pediatric Infect Dis Soc</i>. 2018;7(3):e92-e101. doi:10.1093/jpids/piy056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/29939314/pubmed" id="29939314" target="_blank">29939314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33951360">
<a name="33951360"></a>Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. <i>N Engl J Med</i>. 2021;384(18):1705-1718. doi:10.1056/NEJMoa2033400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/33951360/pubmed" id="33951360" target="_blank">33951360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20876627">
<a name="20876627"></a>Dryden MS. Complicated skin and soft tissue infection. <i>J Antimicrob Chemother</i>. 2010;65(suppl 3):iii35-44. doi:10.1093/jac/dkq302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/20876627/pubmed" id="20876627" target="_blank">20876627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31629365">
<a name="31629365"></a>Durukan D, Read TRH, Murray G, et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5 g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability. <i>Clin Infect Dis</i>. 2020;71(6):1461-1468. doi:10.1093/cid/ciz1031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/31629365/pubmed" id="31629365" target="_blank">31629365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29997980">
<a name="29997980"></a>Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. <i>J Thorac Dis</i>. 2018;10(5):3102-3118. doi:10.21037/jtd.2018.05.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/29997980/pubmed" id="29997980" target="_blank">29997980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.2020">
<a name="File.2020"></a>File TM Jr. Treatment of community-acquired pneumonia in adults in the outpatient setting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26666259">
<a name="26666259"></a>Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society (CFF/ECFS) consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i>. 2016;71(suppl 1):i1-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/26666259/pubmed" id="26666259" target="_blank">26666259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics</a>. Published July 26, 2016. Accessed November 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93. doi:10.1093/cid/cir073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15585448">
<a name="15585448"></a>Friedrich LV, Dougherty R. Fatal Hypoglycemia Associated With Levofloxacin. <i>Pharmacotherapy</i>. 2004;24(12):1807-1812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/15585448/pubmed" id="15585448" target="_blank">15585448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16206101">
<a name="16206101"></a>Frothingham R. Glucose Homeostasis Abnormalities Associated With Use of Gatifloxacin. <i>Clin Infect Dis</i>. 2005;41(9):1269-1276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/16206101/pubmed" id="16206101" target="_blank">16206101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15347636">
<a name="15347636"></a>Fuhrmann V, Schenk P, Jaeger W, Ahmed S, Thalhammer F. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. <i>J Antimicrob Chemother.</i> 2004;54(4):780-784. doi:10.1093/jac/dkh421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/15347636/pubmed" id="15347636" target="_blank">15347636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23401309">
<a name="23401309"></a>Garazzino S, Scolfaro C, Raffaldi I, Barbui AM, Luccoli L, Tovo PA. Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience. <i>Pediatr Pulmonol</i>. 2014;49(4):372-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/23401309/pubmed" id="23401309" target="_blank">23401309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12917240">
<a name="12917240"></a>Garrison MW. Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. <i>J Antimicrob Chemother.</i> 2003;52(3):503-506. doi:10.1093/jac/dkg380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/12917240/pubmed" id="12917240" target="_blank">12917240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15230648">
<a name="15230648"></a>Gavin JR 3rd, Kubin R, Choudhri S, et al. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. <i>Drug Saf</i>. 2004;27(9):671-686.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/15230648/pubmed" id="15230648" target="_blank">15230648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16185172">
<a name="16185172"></a>Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in Inpatients After Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study. <i>Pharmacotherapy</i>. 2005;25(10):1296-1302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/16185172/pubmed" id="16185172" target="_blank">16185172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35284983">
<a name="35284983"></a>Greenberg RG, Landersdorfer CB, Rivera-Chaparro N, et al. Population pharmacokinetics of moxifloxacin in children. <i>Paediatr Drugs</i>. 2022;24(2):163-173. doi:10.1007/s40272-022-00493-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/35284983/pubmed" id="35284983" target="_blank">35284983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26785402">
<a name="26785402"></a>Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. <i>Ann Intern Med.</i> 2016;164(6):425-434. doi:10.7326/M15-1840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/26785402/pubmed" id="26785402" target="_blank">26785402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054853">
<a name="29054853"></a>Haworth CS, Banks J, Capstick T, et al. British Thoracic Society (BTS) guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). <i>Thorax</i>. 2017;72(suppl 2):ii1‐ii64. doi:10.1136/thoraxjnl-2017-210927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/29054853/pubmed" id="29054853" target="_blank">29054853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24447897">
<a name="24447897"></a>Hendricks KA, Wright ME, Shadomy SV, et al; Workgroup on Anthrax Clinical Guidelines. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect Dis</i>. 2014;20(2):e130687. doi:10.3201/eid2002.130687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/24447897/pubmed" id="24447897" target="_blank">24447897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19072244">
<a name="19072244"></a>High KP, Bradley SF, Gravenstein S, et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;48(2):149-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/19072244/pubmed" id="19072244" target="_blank">19072244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22429465">
<a name="22429465"></a>Hooper CY, Lightman SL, Pacheco P, Tam PM, Khan A, Taylor SR. Adjunctive antibiotics in the treatment of acute bacterial endophthalmitis following cataract surgery. <i>Acta Ophthalmol</i>. 2012;90(7):e572-e573. doi:10.1111/j.1755-3768.2011.02365.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/22429465/pubmed" id="22429465" target="_blank">22429465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25491170">
<a name="25491170"></a>Hos NJ, Bauer C, Liebig T, Plum G, Seifert H, Hampl J. Autoinfection as a cause of postpartum subdural empyema due to <i>Mycoplasma hominis</i>. <i>Infection</i>. 2015;43(2):241-244. doi:10.1007/s15010-014-0713-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/25491170/pubmed" id="25491170" target="_blank">25491170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27940800">
<a name="27940800"></a>Jackson MA, Schutze GE, Committee on Infectious Disease. The use of systemic and topical fluoroquinolones. <i>Pediatrics</i>. 2016;138(5).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/27940800/pubmed" id="27940800" target="_blank">27940800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18824619">
<a name="18824619"></a>Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of <i>Mycoplasma genitalium</i> infection: an open study. <i>Int J STD AIDS</i>. 2008;19(10):676-679.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/18824619/pubmed" id="18824619" target="_blank">18824619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23358983">
<a name="23358983"></a>Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC Infectious Diseases Group trial XV. <i>J Clin Oncol</i>. 2013;31(9):1149-1156. doi:10.1200/JCO.2012.45.8109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/23358983/pubmed" id="23358983" target="_blank">23358983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766835">
<a name="12766835"></a>Khaliq Y, Zhanel GG. Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature. <i>Clin Infect Dis</i>. 2003;36(11):1404-1410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/12766835/pubmed" id="12766835" target="_blank">12766835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33122341">
<a name="33122341"></a>Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. <i>Postgrad Med J</i>. 2021;97(1149):452-458. doi:10.1136/postgradmedj-2020-138661<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/33122341/pubmed" id="33122341" target="_blank">33122341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10049286">
<a name="10049286"></a>Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. <i>Antimicrob Agents Chemother.</i> 1999;43(3):672-677. doi:10.1128/AAC.43.3.672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/10049286/pubmed" id="10049286" target="_blank">10049286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16269178">
<a name="16269178"></a>Lawrence KR, Adra M, Keir C. Hypoglycemia-Induced Anoxic Brain Injury Possibly Associated With Levofloxacin. <i>J Infect</i>. 2006;52(6):e177-e180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/16269178/pubmed" id="16269178" target="_blank">16269178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30213330">
<a name="30213330"></a>Lee CC, Lee MG, Hsieh R, et al. Oral fluoroquinolone and the risk of aortic dissection. <i>J Am Coll Cardiol</i>. 2018;72(12):1369-1378. doi:10.1016/j.jacc.2018.06.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/30213330/pubmed" id="30213330" target="_blank">30213330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis</i>. 2012;54(12):e132-e173. doi:10.1093/cid/cis346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17553812">
<a name="17553812"></a>Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.<i> J Antimicrob Chemother</i>. 2007;60(2):370-376. doi:10.1093/jac/dkm130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/17553812/pubmed" id="17553812" target="_blank">17553812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10381104">
<a name="10381104"></a>Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. <i>J Antimicrob Chemother</i>. 1999;43(1):79-86. doi:10.1093/jac/43.1.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/10381104/pubmed" id="10381104" target="_blank">10381104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32702756">
<a name="32702756"></a>Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. <i>Blood</i>. 2020;136(11):1225-1240. doi:10.1182/blood.2019000944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/32702756/pubmed" id="32702756" target="_blank">32702756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11557500">
<a name="11557500"></a>Malone RS, Fish DN, Abraham E, et al. Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients. <i>Antimicrob Agents Chemother</i>. 2001;45(10):2949-2954.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/11557500/pubmed" id="11557500" target="_blank">11557500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22080266">
<a name="22080266"></a>Manhart LE, Broad JM, Golden MR. <i>Mycoplasma genitalium:</i> Should We Treat and How? <i>Clin Infect Dis</i>. 2011;53(suppl 3):129-142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/22080266/pubmed" id="22080266" target="_blank">22080266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.2020">
<a name="Mann.2020"></a>Mann WJ. Overview of preoperative evaluation and preparation for gynecologic surgery. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Martin.2020">
<a name="Martin.2020"></a>Martin DH. Mycoplasma genitalium infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society (SIS) revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24457117">
<a name="24457117"></a>Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/24457117/pubmed" id="24457117" target="_blank">24457117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459437">
<a name="32459437"></a>Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):1444-1453. doi:10.1097/AOG.0000000000003890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/32459437/pubmed" id="32459437" target="_blank">32459437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16185173">
<a name="16185173"></a>Mohr JF, McKinnon PS, Peymann PJ, et al. A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone. <i>Pharmacotherapy</i>. 2005;25(10):1303-1309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/16185173/pubmed" id="16185173" target="_blank">16185173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34183510">
<a name="34183510"></a>Mora-López L, Ruiz-Edo N, Estrada-Ferrer O, et al; DINAMO-study Group. Efficacy and safety of nonantibiotic outpatient treatment in mild acute diverticulitis (DINAMO-study): a multicentre, randomised, open-label, noninferiority trial. <i>Ann Surg</i>. 2021;274(5):e435-e442. doi:10.1097/SLA.0000000000005031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/34183510/pubmed" id="34183510" target="_blank">34183510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moxifloxacin.1">
<a name="Moxifloxacin.1"></a>Moxifloxacin in freeflex bags [prescribing information]. Lake Zurich, IL: Fresenius Kabi; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Moxifloxacin in sodium chloride 0.8% injection [prescribing information]. Morgantown, WV: Mylan Institutional LLC; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Breckenridge.1">
<a name="Breckenridge.1"></a>Moxifloxacin tablet [prescribing information]. Berlin, CT: Breckenridge Pharmaceutical Inc; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27516382">
<a name="27516382"></a>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-e195. doi:10.1093/cid/ciw376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/27516382/pubmed" id="27516382" target="_blank">27516382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31729908">
<a name="31729908"></a>Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. <i>Am J Respir Crit Care Med</i>. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/31729908/pubmed" id="31729908" target="_blank">31729908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34264565">
<a name="34264565"></a>Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al; Contributors. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. <i>MMWR Recomm Rep</i>. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/34264565/pubmed" id="34264565" target="_blank">34264565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20426751">
<a name="20426751"></a>Nemutlu E, Kir S, Eroglu H, et al. Comparison of pharmacokinetic profiles of moxifloxacin in caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. <i>Comb Chem High Throughput Screen</i>. 2010;13(6):502-509.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/20426751/pubmed" id="20426751" target="_blank">20426751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30865791">
<a name="30865791"></a>Nunn AJ, Phillips PPJ, Meredith SK, et al; STREAM Study Collaborators. A trial of a shorter regimen for rifampin-resistant tuberculosis. <i>N Engl J Med</i>. 2019;380(13):1201-1213. doi:10.1056/NEJMoa1811867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/30865791/pubmed" id="30865791" target="_blank">30865791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16936293">
<a name="16936293"></a>Odenholt I, Cars O. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. <i>J Antimicrob Chemother.</i> 2006;58(5):960-965. doi:10.1093/jac/dkl356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/16936293/pubmed" id="16936293" target="_blank">16936293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20598025">
<a name="20598025"></a>Ozyüncü O, Beksac MS, Nemutlu E, Katlan D, Kir S. Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime. <i>J Obstet Gynaecol Res</i>. 2010a;36(3):484-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/20598025/pubmed" id="20598025" target="_blank">20598025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20418070">
<a name="20418070"></a>Ozyüncü O, Nemutlu E, Katlan D, Kir S, Beksac MS. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone. <i>Int J Antimicrob Agents</i>. 2010b;36(2):175-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/20418070/pubmed" id="20418070" target="_blank">20418070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24841264">
<a name="24841264"></a>Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. <i>Antimicrob Agents Chemother</i>. 2014;58(8):4392-4398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/24841264/pubmed" id="24841264" target="_blank">24841264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16510739">
<a name="16510739"></a>Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. <i>N Engl J Med</i>. 2006;354(13):1352-1361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/16510739/pubmed" id="16510739" target="_blank">16510739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26865283">
<a name="26865283"></a>Patel K, Goldman JL. Safety concerns surrounding quinolone use in children. <i>J Clin Pharmacol</i>. 2016;56(9):1060-1075. doi:10.1002/jcph.715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/26865283/pubmed" id="26865283" target="_blank">26865283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.2020">
<a name="Pemberton.2020"></a>Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34286843">
<a name="34286843"></a>Radtke KK, Hesseling AC, Winckler JL, et al. Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. <i>Clin Infect Dis</i>. 2022;74(8):1372-1381. doi:10.1093/cid/ciab641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/34286843/pubmed" id="34286843" target="_blank">34286843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11642690">
<a name="11642690"></a>Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. <i>Pharmacotherapy</i>. 2001;21(10 Pt 2):233S-252S. doi:10.1592/phco.21.16.233s.33992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/11642690/pubmed" id="11642690" target="_blank">11642690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg. </i>2015;152(2)(suppl):S1-S39. doi:10.1177/0194599815572097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med</i>. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879279">
<a name="23879279"></a>Sedlak T, Shufelt C, Iribarren C, et al. Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval. <i>Ann Noninvasive Electrocardiol</i>. 2013;18(4):389-398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/23879279/pubmed" id="23879279" target="_blank">23879279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sethi.2020">
<a name="Sethi.2020"></a>Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28719679">
<a name="28719679"></a>Shah SD, Cifu AS. Management of acute diverticulitis. <i>JAMA</i>. 2017;318(3):291-292. doi:10.1001/jama.2017.6373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/28719679/pubmed" id="28719679" target="_blank">28719679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America (IDSA). <i>Clin Infect Dis</i>. 2010;50(2):133-164. doi:10.1086/649554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27742641">
<a name="27742641"></a>Srivastava S, Deshpande D, Pasipanodya J, Nuermberger E, Swaminathan S, Gumbo T. Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: Goldilocks. <i>Clin Infect Dis</i>. 2016;63(suppl 3):S102-S109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/27742641/pubmed" id="27742641" target="_blank">27742641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555469">
<a name="17555469"></a>Stass H, Bührmann S, Mitchell A, et al. The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction. <i>Br J Clin Pharmacol.</i> 2007;64(6):745-749. doi:10.1111/j.1365-2125.2007.02902.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/17555469/pubmed" id="17555469" target="_blank">17555469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18501909">
<a name="18501909"></a>Stass H, Kubitza D, Aydeniz B, et al. Penetration and accumulation of moxifloxacin in uterine tissue. <i>Int J Gynaecol Obstet</i>. 2008;102(2):132-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/18501909/pubmed" id="18501909" target="_blank">18501909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11874385">
<a name="11874385"></a>Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. <i>Br J Clin Pharmacol.</i> 2002;53(3):232-237. doi:10.1046/j.0306-5251.2001.01557.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/11874385/pubmed" id="11874385" target="_blank">11874385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30681729">
<a name="30681729"></a>Stass H, Lettieri J, Vanevski KM, et al. Pharmacokinetics, safety, and tolerability of single-dose intravenous moxifloxacin in pediatric patients: dose optimization in a phase 1 study. <i>J Clin Pharmacol.</i> 2019;59(5):654-667. doi:10.1002/jcph.1358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/30681729/pubmed" id="30681729" target="_blank">30681729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26453777">
<a name="26453777"></a>Stollman N, Smalley W, Hirano I; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of acute diverticulitis. <i>Gastroenterology</i>. 2015;149(7):1944-1949. doi:10.1053/j.gastro.2015.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/26453777/pubmed" id="26453777" target="_blank">26453777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stout.1">
<a name="Stout.1"></a>Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7800023">
<a name="7800023"></a>Szarfman A, Chen M, Blum MD. More on Fluoroquinolone Antibiotics and Tendon Rupture. <i>N Engl J Med</i>. 1995;332(3):193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/7800023/pubmed" id="7800023" target="_blank">7800023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30179565">
<a name="30179565"></a>Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update.<i> J Clin Oncol</i>. 2018;36(30):3043-3054. doi:10.1200/JCO.18.00374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/30179565/pubmed" id="30179565" target="_blank">30179565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25362206">
<a name="25362206"></a>Thee S, Garcia-Prats AJ, Draper HR, et al. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. <i>Clin Infect Dis</i>. 2015;60(4):549-556. doi:10.1093/cid/ciu868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/25362206/pubmed" id="25362206" target="_blank">25362206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28566592">
<a name="28566592"></a>Tokimatsu I, Shigemura K, Kotaki T, et al. A prospective study of the efficacy, safety and pharmacokinetics of enteral moxifloxacin in the treatment of hemodialysis patients with pneumonia. <i>Intern Med</i>. 2017;56(11):1315-1319. doi:10.2169/internalmedicine.56.8369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/28566592/pubmed" id="28566592" target="_blank">28566592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18584553">
<a name="18584553"></a>Torres JR, Bajares A. Severe acute polyarthritis in a child after high doses of moxifloxacin. <i>Scand J Infect Dis</i>. 2008;40(6-7):582-584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/18584553/pubmed" id="18584553" target="_blank">18584553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy. <i> Clin Infect Dis</i>. 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284. doi:10.1086/425368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed June 17, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073652">
<a name="32073652"></a>van Dijk ST, Chabok A, Dijkgraaf MG, Boermeester MA, Smedh K. Observational versus antibiotic treatment for uncomplicated diverticulitis: an individual-patient data meta-analysis. <i>Br J Surg</i>. 2020;107(8):1062-1069. doi:10.1002/bjs.11465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/32073652/pubmed" id="32073652" target="_blank">32073652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28331037">
<a name="28331037"></a>van Kampenhout E, Bolhuis MS, Alffenaar JC, et al. Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. <i>Eur Respir J</i>. 2017;49(3).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/28331037/pubmed" id="28331037" target="_blank">28331037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19768381">
<a name="19768381"></a>Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, et al; STIC Study Group. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. <i>Infection</i>. 2009;37(5):407-417. doi:10.1007/s15010-009-8468-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/19768381/pubmed" id="19768381" target="_blank">19768381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Waites.2020">
<a name="Waites.2020"></a>Waites KB, Ambalavanan N. Mycoplasma hominis and Ureaplasma infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16775443">
<a name="16775443"></a>Wang S, Rizvi AA. Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient. <i>Am J Med Sci</i>. 2006;331(6):334-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/16775443/pubmed" id="16775443" target="_blank">16775443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.2020">
<a name="Weintrob.2020"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 27, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35404556">
<a name="35404556"></a>WHO consolidated guidelines on tuberculosis: Module 5: Management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/35404556/pubmed" id="35404556" target="_blank">35404556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wiesenfeld.2020">
<a name="Wiesenfeld.2020"></a>Wiesenfeld HC. Pelvic inflammatory disease: treatment in adults and adolescents. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31310051">
<a name="31310051"></a>Willmann S, Frei M, Sutter G, et al. Application of physiologically-based and population pharmacokinetic modeling for dose finding and confirmation during the pediatric development of moxifloxacin. <i>CPT Pharmacometrics Syst Pharmacol</i>. 2019;8(9):654-663. doi:10.1002/psp4.12446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/31310051/pubmed" id="31310051" target="_blank">31310051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilson.1">
<a name="Wilson.1"></a>Wilson KH. Prevention of anthrax. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22135277">
<a name="22135277"></a>Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. <i>Eur Respir J</i>. 2012;40(1):17-27. doi:10.1183/09031936.00090311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/22135277/pubmed" id="22135277" target="_blank">22135277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29356761">
<a name="29356761"></a>Wirth S, Emil SGS, Engelis A, et al. Moxifloxacin in pediatric patients with complicated intra-abdominal infections: results of the MOXIPEDIA randomized controlled study. <i>Pediatr Infect Dis J</i>. 2018;37(8):e207-e213. doi:10.1097/INF.0000000000001910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/29356761/pubmed" id="29356761" target="_blank">29356761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment. https://www.who.int/publications/i/item/9789240007048. Published June 15, 2020. Accessed August 27, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30642271">
<a name="30642271"></a>Xiang L, Lu B. Infection due to <i>Mycoplasma hominis</i> after left hip replacement: case report and literature review. <i>BMC Infect Dis</i>. 2019;19(1):50. doi:10.1186/s12879-019-3686-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/30642271/pubmed" id="30642271" target="_blank">30642271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15252190">
<a name="15252190"></a>Zacher JL and Givone DM, “False-Positive Urine Opiate Screening Associated with Fluoroquinolone Use,” <i>Ann Pharmacother</i>, 2004, 38:1525-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-systemic-pediatric-drug-information/abstract-text/15252190/pubmed" id="15252190" target="_blank">15252190</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 113351 Version 230.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
